IL4R and Alzheimer disease: Dupilumab (anti–IL-4Rα), which inhibits the shared IL-4 and IL-13 receptor, is approved for AD (31); tralokinumab (anti–IL-13) has been submitted for approval (56); and lebrikizumab (anti–IL-13) is currently in phase III trials for AD (57, 58).